Investigational agents in metastatic basal cell carcinoma: focus on vismodegib

Vismodegib (GDC-0449, 2-chloro-N-(4-chloro-3-(pyridin-2-yl)phenyl)-4-(methylsulfonyl)benzamide, Erivedge™) is a novel first-in-human, first-in class, orally bio-available Hedgehog pathway signaling inhibitor of the G-protein coupled receptor-like protein smoothened (SMO) which was approved in the Un...

Descripción completa

Detalles Bibliográficos
Autores principales: Batty, Nicolas, Kossoff, Ellen, Dy, Grace K
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2012
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4863308/
https://www.ncbi.nlm.nih.gov/pubmed/27186122
http://dx.doi.org/10.2147/JEP.S26591

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4863308/
https://www.ncbi.nlm.nih.gov/pubmed/27186122
http://dx.doi.org/10.2147/JEP.S26591

Ejemplares similares